Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 3/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718787 | 0.89 | ALOX5 (0.43) | BACE1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL24772554 | 0.87 | ALOX5 (0.41) | ALDH1A1BACE1CYP1A2KDM5APHF8 | |
| SCHEMBL17624924 | 0.83 | ALDH1A1 (0.44) | ALDH1A1CYP1A2KMT2A | |
| SCHEMBL14923343 | 0.82 | MEN1 (0.48) | ALDH1A1BACE1KDM5APHF8KDM2A | |
| SCHEMBL14321939 | 0.82 | ALOX5 (0.46) | ALDH1A1BACE1CYP1A2KDM5APHF8 | |
| SCHEMBL11892779 | 0.80 | ALOX5 (0.44) | ALDH1A1BACE1KDM5APHF8KDM2A | |
| SCHEMBL2933581 | 0.77 | ALOX5 (0.44) | ALDH1A1BACE1KDM5APHF8KDM2A | |
| SCHEMBL21568851 | 0.74 | ALOX5 (0.48) | ALDH1A1KDM5APHF8KDM2AKDM4C | |
| SCHEMBL3373961 | 0.74 | ALOX5 (0.48) | ALDH1A1KDM5APHF8KDM2AKDM4C | |
| SCHEMBL2718690 | 0.74 | ALOX5 (0.48) | ALOX5SIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | ALDH1A1 1846/4885BACE1 1/4885CYP1A2 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.